



مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

ATEZOlizumab (Tecentriq®)



Ministry of Health

Name:

File #:

Ht (cm):

Nationality:

Civil ID:

Wt (Kg):

Gender/Age:

DOB:

BSA (m²):

Indication(s): Advanced stage NSCLC.

Extensive Stage SCLC (combined With Etoposide/CARBOplatin).

Urothelial Cacrcinoma.

Triple-Negative Breast Cancer (combined with NAB-PACLitaxel/CARBOplatin).

Central line: Available NA

Allergies: NKA Yes, specify; _____

Standard Protocol:

DRUG	DOSE	ADMINISTRATION	DAYS
ATEZOlizumab	1200 mg	IV in 250 mL NS over 60 min. If the initial infusion is well tolerated, shorten the subsequent infusions to 30 min.	D1
To be repeated every 3 weeks till disease progression or intolerable toxicities.			

Treatment Description:

Cycle	Date	ATEZOlizumab	Physician	Consultant
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				
C# __				

Important Notes:

Reported grade 3/4 toxicities: None Hematological Non-Hematological

If yes; Did it indicate hospitalization? Yes No

Did it indicate chemo-delay for ≥ 7 days? Yes No

Did it indicate dose reduction? Yes No

Did it indicate G-CSF support? Yes No